转移性去势抵抗性前列腺癌多西他赛治疗期间雄激素下降与生存的关系
基于CALGB 90401试验中1050例接受多西他赛联合泼尼松及贝伐珠单抗或安慰剂治疗的mCRPC患者数据,评估血清雄激素(睾酮、雄烯二酮、DHEA)从基线至6周下降与总生存的关系。结果显示睾酮下降幅度与OS独立相关,每单位6周/基线比值增加死亡HR为1.02(95%CI 1.01-1.03,p=0.001),雄烯二酮和DHEA下降非显著预测因子。
要点
- 多西他赛治疗期间睾酮下降与更长生存相关,支持CRPC中较高血清雄激素具有利预后意义。
- 6周/基线睾酮比值每增加1单位,死亡HR为1.02(95%CI 1.01-1.03,p=0.001)。
- 雄烯二酮和DHEA下降未显著预测OS;6周/基线睾酮比值预测PSA下降≥50%的OR为0.93(95%CI 0.85-0.98,p=0.039)。
核心结论
- 多西他赛治疗期间睾酮下降与更长总生存相关,与CRPC中较高血清雄激素具有利预后意义一致。
研究设计与样本
- 评估CALGB 90401试验中1050例接受多西他赛、泼尼松及贝伐珠单抗或安慰剂治疗的mCRPC患者数据。
- 入组要求为进展性mCRPC且既往未接受化疗。
- 采用串联液相色谱-质谱联用(LC-MS/MS)检测基线、6周及进展时血清睾酮、雄烯二酮和DHEA。
- 计算6周与基线雄激素水平的比值,采用比例风险模型评估其预测OS的预后意义并校正已知预后因素。
主要发现
- 睾酮、雄烯二酮和DHEA的中位基线值分别为1.0、13.5和8.1 ng/dL,6周水平分别为0.64、7.0和6.8 ng/dL。
- 低睾酮下降组中位OS为20.9个月,高睾酮下降组为26.3个月。
- 多变量分析中,睾酮水平变化与更长OS独立相关;6周/基线比值每增加1单位,死亡HR为1.02(95%CI 1.01-1.03,p=0.001)。
- 雄烯二酮和DHEA下降不是OS的显著预测因子。
- 多变量分析中血清变化未预测PFS,但6周/基线睾酮比值预测PSA下降≥50%的OR为0.93(95%CI 0.85-0.98,p=0.039)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Multiple androgens drive prostate cancer progression and higher pre-treatment levels of androgens, even within the castrate range, have been previously shown to be associated with an improved overall survival (OS) in mCRPC. Docetaxel impairs microtubules, has androgen receptor (AR) inhibitory effects and is used in both the castration resistant and sensitive settings, where androgen dynamics may impact outcome. The present analysis evaluates the association of decline in serum androgen levels (Testosterone (T), Androstenedione (A) and DHEA in docetaxel-treated mCRPC patients with OS. METHODS: Data from 1050 men treated on CALGB 90401 with docetaxel, prednisone and either bevacizumab or placebo were evaluated. Eligibility required progressive mCRPC and no prior chemotherapy. Pre-treatment, 6 week and progression serum assays for T, A and DHEA were performed via tandem Liquid Chromatography-Mass Spectrometry (LC-MS/MS). Changes in T, A and DHEA levels from baseline to 6 weeks were calculated as the ratio of 6-week over baseline. The proportional hazards model was used to assess the prognostic significance of changes in T, A, and DHEA from baseline to 6 weeks in predicting OS adjusting for known prognostic factors. RESULTS: Median baseline values for T, A, and, DHEA were 1.0, 13.5, and 8.1 ng/dL respectively while 6 week levels were 0.64, 7.0, and 6.8 ng/dL respectively. Median OS for low testosterone decline is 20.9 months vs 26.3 months for high testosterone decline. In multivariable analysis including known prognostic variables, change in testosterone levels was independently associated with greater OS; the hazard ratio for death with each unit increase in the 6-week/baseline ratio is 1.02 (95% CI = 1.01-1.03, p = 0.001). Decline in A and DHEA were not significant predictors of OS. In multivariable analysis change in the serum changes did not predict PFS however the ratio of T at 6-weeks over baseline was prognostic of ≥50% decline in PSA with an odds ratio of 0.93 (95% CI = 0.85-0.98, p-value = 0.039). CONCLUSIONS: Declines in testosterone during docetaxel treatment is associated with a longer survival, consistent with a favorable prognostic significance of higher serum androgens in the CRPC.
引用
- Ryan CJ, Dutta S, Kelly WK, et al. Androgen decline and survival during docetaxel therapy in metastatic castration resistant prostate cancer (mCRPC). Prostate Cancer Prostatic Dis. 2019. PMID: 31053766. doi:10.1038/s41391-019-0152-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。